Valneva SE ADR Earnings
The next earnings date for Valneva SE ADR has not yet been scheduled.
Analyst Estimates of Valneva SE ADR Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Valneva SE ADR Earnings: Historical
| 08/13/2026 | Before Market | $-0.40 | -42.86% |
| 05/13/2026 | After Market | $-0.42 | -100.00% |
| 03/19/2026 | --- | $-0.67 | -81.80% |
| 11/20/2025 | Before Market | $-0.60 | -130.77% |
| 08/12/2025 | Before Market | $-0.16 | 15.79% |
| 05/07/2025 | --- | $-0.06 | 71.10% |
| 03/20/2025 | Before Market | $-0.54 | -237.50% |
| 11/07/2024 | Before Market | $-0.15 | 6.25% |
| 08/13/2024 | Before Market | $-0.37 | -68.18% |
| 05/07/2024 | After Market | $0.88 | 66.04% |
More About Valneva SE ADR
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
“Valneva SE ADR Earnings” Can Refer to the Valneva SE ADR Earnings Date
Some people say “Valneva SE ADR earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Valneva SE ADR position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Valneva SE ADR Stock on the Earnings Date
If you own Valneva SE ADR stock (VALN) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Valneva SE ADR might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Valneva SE ADR shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Valneva SE ADR Earnings
You can contact us any time if you would like to ask questions about Valneva SE ADR earnings or anything else related to the stock market.